Pharmaceutical News

RSS

FDA approves expanded use of Gardasil 9 for adults aged 27 to 45 years

The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years.

6 Oct 2018

FDA approves HEMLIBRA for treatment of hemophilia A

Chugai Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.

5 Oct 2018

Clemson University researcher reveals insights into rapid spread of homemade steroids

A Clemson University researcher recently published insights into homemade steroids and steroid trafficking through a study of federal court cases. The research details why homemade steroids became popular and how online tools and cryptocurrency have allowed for their rapid spread.

4 Oct 2018

Low-dose aspirin use associated with reduced ovarian cancer risk

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported taking a low-dose aspirin every day had a 23 percent lower risk of ovarian cancer compared to nonaspirin users.

4 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

4 Oct 2018

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Berlin, Germany, and published in The Lancet, shows that the appetite-suppressant drug lorcaserin decreases risk of developing diabetes and increases the rates of remission of high blood sugar.

4 Oct 2018

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

At the 2018 Meeting of the European Association for the Study of Diabetes, Brigham and Women's Hospital investigators from the Thrombolysis in Myocardial Infarction Study Group presented diabetes-related findings from CAMELLIA-TIMI 61, a clinical trial of overweight and obese patients designed to test lorcaserin, a weight loss drug manufactured by the trial's sponsor, Eisai Inc.

4 Oct 2018

Australia will soon become the first country to eradicate cervical cancer

According to an announcement from the International Papillomavirus Society, Australia could soon become the first country to eradicate cervical cancer.

4 Oct 2018

New ReFRAME drug repurposing collection offers hope for treating major diseases

Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?

4 Oct 2018

Eagle Pharmaceuticals and USAMRICD signs agreement to assess neuroprotective effects of RYANODEX

Eagle Pharmaceuticals, Inc. today announced that it has entered into an agreement with the United States Army Medical Research Institute of Chemical Defense, the nation's leading science and technology laboratory in the area of medical chemical countermeasures research and development, to conduct a study to evaluate the neuroprotective effects of RYANODEX.

3 Oct 2018

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Therapure Biomanufacturing, an integrated contract development and manufacturing organization and a division of Therapure Biopharma Inc., today announced approval for the manufacturing of Insmed Incorporated's ARIKAYCE® at its Mississauga facility by the U.S. Food and Drug Administration.

3 Oct 2018

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

New research presented at the annual meeting of the European Association for the Study of Diabetes and published simultaneously in The Lancet Diabetes & Endocrinology shows how the glucose-lowering drug lixisenatide can slow or prevent damage to the kidneys in macro-albuminuric patients with type 2 diabetes mellitus and cardiovascular disease.

3 Oct 2018

VA adding opioid antidote to defibrillator cabinets for quicker overdose response

It took more than 10 minutes for paramedics to arrive after a housekeeper found a man collapsed on the floor of a bathroom in a Boston Veteran Affairs building.

3 Oct 2018

Natural compound found in grapes may protect against cancer

Lung cancer is the deadliest form of cancer in the world, and 80% of death are related to smoking. In addition to tobacco control, effective chemoprevention strategies are therefore needed.

3 Oct 2018

Generics manufacturer Zentiva becomes an independent organization

Today marks generics manufacturer Zentiva's first day as an independent organization, following completion of the company's previously announced divestment from Sanofi.

3 Oct 2018

Researchers find ALS drug as potential treatment for prostate cancer

Researchers have discovered a new use for an old drug as a potential treatment for prostate cancer. The findings are published in the journal The Prostate.

3 Oct 2018

Spero Health launched to tackle the rising opioid crisis

Spero Health, Inc., a newly formed healthcare organization specializing in local, affordable, outpatient care for individuals suffering from substance use disorder, announced that it has acquired investment growth capital to meet the demand in communities across the country for high-quality, comprehensive and integrated addiction treatment services.

3 Oct 2018

Researchers assess effects of adding dapagliflozin to metformin or insulin in type 2 diabetes patients

Researchers used continuous glucose monitoring to assess the effects of adding dapagliflozin to a regimen of either metformin or insulin in patients with type 2 diabetes and found significant reductions in mean glucose and other glycemic factors, with greater improvements seen in patients taking metformin compared to insulin.

3 Oct 2018

New supplemental health products launched to complement Anthem medical plans

Anthem Blue Cross and Blue Shield now offers employer-sponsored voluntary accident, critical illness and hospital indemnity insurance products, for effective dates beginning January 1, 2019.

3 Oct 2018

Pharmaceutical News

FDA approves expanded use of Gardasil 9 for adults aged 27 to 45 years

FDA approves HEMLIBRA for treatment of hemophilia A

Clemson University researcher reveals insights into rapid spread of homemade steroids

Low-dose aspirin use associated with reduced ovarian cancer risk

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

Appetite-suppressant drug reduces diabetes risk and increases remission rates of blood sugar

Weight loss drug reduces risk of diabetes in patients with pre-diabetes, finds study

Australia will soon become the first country to eradicate cervical cancer

New ReFRAME drug repurposing collection offers hope for treating major diseases

Eagle Pharmaceuticals and USAMRICD signs agreement to assess neuroprotective effects of RYANODEX

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

VA adding opioid antidote to defibrillator cabinets for quicker overdose response

Natural compound found in grapes may protect against cancer

Generics manufacturer Zentiva becomes an independent organization

Researchers find ALS drug as potential treatment for prostate cancer

Spero Health launched to tackle the rising opioid crisis

Researchers assess effects of adding dapagliflozin to metformin or insulin in type 2 diabetes patients

New supplemental health products launched to complement Anthem medical plans

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News